Sean Heffron is a Cardiology physician affiliated with NYU Langone Health. OpenAlex indexes 103 publications with 1,045 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
530 1st Ave Ste 4f
New York, NY 100166402
Telephone
212-263-0855Provider last certified this registry record 3 May 2021.
Clinical trials
- A Pilot Feasibility and Acceptability Study of Remote ExerciSe Training mOdalities (PRESTO)
Sponsor: NYU Langone Health
- Pro-rEsolving and pRo-inflammatory reSPonses to Acute exhaustIve exeRcisE in Healthy Individuals
Sponsor: NYU Langone Health
- Body Weight, Aspirin Dose and Pro-resolving Mediators
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20231 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2017–2025 per NIH RePORTER. The latest:
- Aspirin-triggered Specialized Pro-resolving Mediators in Increasing Weight and Atherosclerotic Cardiovascular Disease
New York University School of Medicine
FY2025$389,980R01HL157430 - Aspirin-triggered Specialized Pro-resolving Mediators in Increasing Weight and Atherosclerotic Cardiovascular Disease
New York University School of Medicine
FY2024$627,717R01HL157430 - Aspirin-triggered Specialized Pro-resolving Mediators in Increasing Weight and Atherosclerotic Cardiovascular Disease
New York University School of Medicine
FY2023$742,967R01HL157430
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
Journal of the American College of Cardiology
2026 - High-Density Lipoprotein Lipid and Protein Cargo and Cholesterol Efflux Capacity Before and After Bariatric Surgery
Arteriosclerosis Thrombosis and Vascular Biology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gareth Morgan, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
Ira Jacobson, MD
NYU Langone Health
Michael Zelefsky, MD
NYU Langone Health
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”